Former CMS admin Slavitt ’s Town Hall Fund closes $115m healthcare fund

Town Hall Ventures, a healthcare-focused investment firm co-founded by former Centers for Medicare and Medicaid Services head Andy Slavitt, said today that it closed its first fund at $115 million. The investment firm, which was formed in May, said that the $115 million it raised exceeded its target size by more than 50%. The firm said it is looking to invest in companies that serve vulnerable populations and look to improve care in Medicare, Medicaid and in risk-based care. “We couldn’t be more excited to have Ann join the team as an investment-focused Vice President. Town Hall’s commitment to building great companies begins with building a great team with diverse thoughts and capabilities. Ann brings depth, intelligence, experience, and great values to our team and has already had an enormous impact,” Slavitt said in a prepared release. Town Hall Ventures said that along with closing the fund, it also added Ann Hickey as a new VP and chose three new companies to invest in. The fund said that it invested in Landmark Health, a home-based care provider, Bright Health, a technology-enabled health insurance plan and Strive Health, which is developing chronic kidney disease solutions. “Town Hall offers a special proposition when considering investment partners for our high growth company. Andy, Trevor, and David all bring unique and complementary areas of expertise and we are thrilled to work with them,” Bright Health founder &CEO Bob Sheeh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Funding Roundup townhallventures Source Type: news

Related Links:

In conclusion, the results of the study showed that urinary alpha-GST and NGAL are promising biomarkers of ON. Ambiguous results of the remaining biomarkers, i.e., urinary pi-GST and KIM-1, and serum NGAL level may be related to a relatively small study group. Their utility in an early diagnosis of ON should be reevaluated. PMID: 30327688 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Conclusions: Our study finds that sevelamer is potentially cost-effective compared to CaCO3, for the treatment of hyperphosphatemia in predialysis CKD III-V. We propose that sevelamer should be an option in the treatment of Malaysian predialysis patients with hyperphosphatemia, particularly those with high calcium load. PMID: 30327732 [PubMed]
Source: International Journal of Nephrology - Category: Urology & Nephrology Tags: Int J Nephrol Source Type: research
Oral Diseases,Volume 0, Issue ja, -Not available-.
Source: Oral Diseases - Category: ENT & OMF Authors: Source Type: research
Conditions:   Metabolic Acidosis;   Chronic Kidney Disease Interventions:   Drug: TRC101;   Drug: Placebo Sponsor:   Tricida, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Kidney Diseases Intervention:   Sponsor:   Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Metabolic Acidosis;   Chronic Kidney Disease Interventions:   Drug: TRC101;   Drug: Placebo Sponsor:   Tricida, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Kidney Diseases Intervention:   Sponsor:   Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: The overall results support a positive association between CKD and AMD, although some limitations exist. Given the risk that AMD is increased in CKD, regular eye screenings for the CKD population is recommended for an early detection and intervention.Am J Nephrol 2018;48:278 –291
Source: American Journal of Nephrology - Category: Neurology Source Type: research
Abstract Kidney diseases including acute kidney injury and chronic kidney disease are among the largest health issues worldwide. Dialysis and kidney transplantation can replace a significant portion of renal function, however these treatments still have limitations. To overcome these shortcomings, a variety of innovative efforts have been introduced, including cell-based therapies. During the past decades, advances have been made in the stem cell and developmental biology, and tissue engineering. As part of such efforts, studies on renal cell therapy and artificial kidney developments have been conducted, and mult...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
AbstractPurpose of ReviewArsenic (As), cadmium (Cd), and lead (Pb) are ubiquitous toxicants with evidence of adverse kidney impacts at high exposure levels. There is less evidence whether environmental exposure to As, Cd, or Pb plays a role in development of chronic kidney disease (CKD). We conducted a systematic review to summarize the recent epidemiologic literature examining the relationship between As, Cd, or Pb with CKD.Recent FindingsWe included peer-reviewed studies published in English between January 2013 and April 2018 for As and Cd, and all dates prior to April 2018 for Pb. We imposed temporality requirements fo...
Source: Current Environmental Health Reports - Category: Environmental Health Source Type: research
More News: Centers for Medicare and Medicaid Services (CMS) | Chronic Kidney Disease | Funding | Health Insurance | Health Management | Insurance | Medicaid | Medicare | Urology & Nephrology